- Home
- TXG
as 02-21-2025 4:00pm EST
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 1.5B | IPO Year: | 2019 |
| Target Price: | $20.36 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.80 - $48.42 | Next Earning Date: | 02-12-2025 |
| Revenue: | $610,785,000 | Revenue Growth: | -1.28% |
| Revenue Growth (this year): | 4.38% | Revenue Growth (next year): | 9.08% |
Latest 10x Genomics Inc. News
TXG Breaking Stock News: Dive into TXG Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
MT Newswires
8 days ago
Morgan Stanley Trims Price Target on 10x Genomics to $26 From $28, Keeps Overweight Rating
Simply Wall St.
8 days ago
10x Genomics Full Year 2024 Earnings: EPS Misses Expectations
Benzinga
9 days ago
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Barrons.com
9 days ago
Trump’s Cuts to Medical Research Are Hurting These Stocks
StockStory
9 days ago
Why 10x Genomics (TXG) Shares Are Falling Today
MT Newswires
9 days ago
UBS Adjusts Price Target on 10x Genomics to $14 From $20, Keeps Neutral Rating
Barrons.com
9 days ago
10x Genomics Shares Tumble on Fear Over Cuts to NIH
Compare TXG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.